Selected article for: "nucleocapsid protein and structural protein"
Author: Julian Braun; Lucie Loyal; Marco Frentsch; Daniel Wendisch; Philipp Georg; Florian Kurth; Stefan Hippenstiel; Manuela Dingeldey; Beate Kruse; Florent Fauchere; Emre Baysal; Maike Mangold; Larissa Henze; Roland Lauster; Marcus Mall; Kirsten Beyer; Jobst Roehmel; Juergen Schmitz; Stefan Miltenyi; Marcel A Mueller; Martin Witzenrath; Norbert Suttorp; Florian Kern; Ulf Reimer; Holger Wenschuh; Christian Drosten; Victor M Corman; Claudia Giesecke-Thiel; Leif-Erik Sander; Andreas Thiel
Title: Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors
  • Document date: 2020_4_22
    • ID: 164yx77a_36
    Snippet: how SARS-CoV-2 specific humoral or cellular immunity mediates durable protection against 192 reinfection is unknown but will be one of the critically important fields of research in the 193 coming months. It has been demonstrated in mouse models that CD4 + as well as CD8 + T cell 194 responses directed against structural proteins such as spike or nucleocapsid protein of CoV critically contribute to viral clearance 17,36,37 . 196.....
    Document: how SARS-CoV-2 specific humoral or cellular immunity mediates durable protection against 192 reinfection is unknown but will be one of the critically important fields of research in the 193 coming months. It has been demonstrated in mouse models that CD4 + as well as CD8 + T cell 194 responses directed against structural proteins such as spike or nucleocapsid protein of CoV critically contribute to viral clearance 17,36,37 . 196

    Search related documents:
    Co phrase search for related documents
    • cellular humoral immunity and mouse model: 1, 2, 3, 4, 5
    • cellular humoral immunity and nucleocapsid spike: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • cellular humoral immunity and nucleocapsid spike protein: 1, 2, 3
    • cellular humoral immunity and SARS specific cellular humoral immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • cellular humoral immunity and specific cellular humoral immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cellular humoral immunity and structural protein: 1, 2, 3
    • cellular humoral immunity and viral clearance: 1, 2, 3, 4, 5, 6, 7, 8
    • CoV nucleocapsid spike protein and mouse model: 1, 2
    • CoV nucleocapsid spike protein and nucleocapsid spike: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • CoV nucleocapsid spike protein and nucleocapsid spike protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • CoV nucleocapsid spike protein and structural protein: 1, 2, 3, 4, 5, 6
    • CoV nucleocapsid spike protein structural protein and mouse model: 1
    • CoV nucleocapsid spike protein structural protein and nucleocapsid spike: 1, 2, 3, 4
    • CoV nucleocapsid spike protein structural protein and nucleocapsid spike protein: 1, 2, 3, 4
    • CoV nucleocapsid spike protein structural protein and structural protein: 1, 2, 3, 4
    • critically important field and research critically important field: 1
    • durable protection and nucleocapsid spike: 1, 2, 3
    • durable protection and structural protein: 1
    • durable protection and viral clearance: 1